Shares of Baxter International BAX rose 1.2% in pre-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share increased 16.90% year over year to $0.83, which beat the estimate of $0.73.
Revenue of $2,972,000,000 up by 4.24% year over year, which beat the estimate of $2,830,000,000.
Outlook
The upcoming fiscal year's EPS expected to be between $3.02 and $3.05.
How To Listen To The Conference Call
Date: Oct 29, 2020
Time: 08:30 AM
Technicals
52-week high: $95.19
Company's 52-week low was at $69.10
Price action over last quarter: down 8.29%
Company Description
Baxter manufactures medical products across seven major reported business segments. The renal segment (32% of 2019 sales) includes peritoneal dialysis and hemodialysis products for chronically ill patients while its acute therapies segment (5%) offers kidney or other organ support tools in intensive care situations. The medication delivery segment (25% of sales) sells IV pumps, administrative sets, and solutions while its nutrition segment (8% of sales) offers parenteral nutrition therapies. The pharmaceuticals segment (19% of sales) offers injectable drugs, anesthetic gases, and compounding services. The advanced surgery segment (8% of sales) provides hemostastic products and biosurgical sealants. Contract manufacturing rounds out the remaining sales.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.